Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a primary focus towards orphan diseases. The company is a leader in the rapidly developing field of individualized cell-based therapies for solid tumors, and is using the ALECSAT platform to generate best-in- class therapeutics to treat cancer with a high unmet medical need.
Cytovac has one ongoing fully enrolled phase II trial and four completed phase I trials.
The completed phase I trial in the aggressive brain cancer, glioblastoma, showed indications of prolonged survival. Glioblastoma has an average median survival of 15 months with today’s treatment.
Phase II data (Progression free survival) for glioblastoma is estimated to be published in H1 2020, and full phase II data is estimated to be published in H1 2021. The target market for glioblastoma is estimated to be USD 300 million.
The upcoming sarcoma and breast cancer study will start directly in phase II due to positive safety profile from previous ALECSAT Phase I studies.
Cytovac is fully preparing for commercialization and has already established an approved GMP manufacturing facility and research department. The management team has extensive experience from commercialization of biotech products with over 10 market approved drugs.